Outlook Therapeutics (OTLK) News Today $5.56 -0.12 (-2.11%) (As of 09/27/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Outlook: How to add or remove birthdays from your calendarSeptember 28 at 7:38 PM | yahoo.comRevenera’s Monetization Monitor 2025 Outlook Highlights Opportunities to Drive ProfitabilitySeptember 26 at 9:55 AM | finance.yahoo.com5 Reasons Why I Schedule My Outlook EmailsSeptember 26 at 9:55 AM | yahoo.comViking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of DataSeptember 25, 2024 | seekingalpha.comMicrosoft Outlook: Best tips and tricks I use to manage my inbox efficientlySeptember 25, 2024 | msn.comGreat Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)Great Point Partners LLC lifted its stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 15.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,701,510 shares of the company's stock after buying an additional 221,5September 24, 2024 | marketbeat.comManage Your Outlook Attachments Like a Pro with These 8 TipsSeptember 23, 2024 | msn.comIntegrated Financial Technologies to Sponsor Auto Finance Summit Market Outlook SessionSeptember 23, 2024 | finance.yahoo.comNielsenIQ Mid-Year Consumer Outlook: Guide to 2025 Reveals Catalysts to Change in Key Verticals Across IndustriesSeptember 23, 2024 | finance.yahoo.comAtlantic Tropical Outlook: South may be impacted by a Gulf stormSeptember 21, 2024 | msn.comThe New Outlook for Windows Isn't Worth Using: 8 Improvements It NeedsSeptember 19, 2024 | msn.comWindows’ new Outlook app: 4 key details you absolutely need to knowSeptember 19, 2024 | msn.comEvilginx Gmail And Outlook Attacks Can Bypass 2FA, Security Expert WarnsSeptember 19, 2024 | forbes.comThird-party email apps are about to lose access to Outlook emailsSeptember 17, 2024 | msn.comOutlook Therapeutics® to Participate in the Virtual Investor Closing Bell SeriesSeptember 16, 2024 | globenewswire.comOutlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference SeriesSeptember 13, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from BrokeragesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target amoSeptember 10, 2024 | marketbeat.comBuy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/LytenavaSeptember 5, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical TrialSeptember 4, 2024 | globenewswire.comOutlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comAscendiant Capital Markets Cuts Outlook Therapeutics (NASDAQ:OTLK) Price Target to $33.00Ascendiant Capital Markets cut their price target on Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday.September 3, 2024 | marketbeat.comOutlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA HurdlesAugust 26, 2024 | seekingalpha.comVanguard Group Inc. Has $4.08 Million Stock Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK)Vanguard Group Inc. lessened its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 94.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 341,300 shares of the company's stock after selliAugust 19, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Post FY2024 Earnings of ($3.90) Per ShareOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Investment analysts at Brookline Capital Management lowered their FY2024 earnings per share estimates for shares of Outlook Therapeutics in a research report issued on Wednesday, August 14th. Brookline Capital Management analyst K. DolliverAugust 19, 2024 | marketbeat.comOutlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comOutlook Therapeutics (NASDAQ:OTLK) Stock Rating Reaffirmed by Chardan CapitalChardan Capital reiterated a "buy" rating and set a $53.00 target price on shares of Outlook Therapeutics in a research report on Friday.August 16, 2024 | marketbeat.comBrokers Offer Predictions for Outlook Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:OTLK)Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Research analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Outlook Therapeutics in a research report issued on Thursday, August 15th. HC Wainwright analyst D. Tsao now anticipates that the company willAugust 16, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from AnalystsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been given an average rating of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the cAugust 16, 2024 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday.August 15, 2024 | marketbeat.comOutlook Therapeutics Poised for Growth: Strong Buy Recommendation Amidst Positive Clinical and Financial DevelopmentsAugust 15, 2024 | markets.businessinsider.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Q3 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deOTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024August 14, 2024 | investorplace.comOutlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comOptimistic Outlook: Jasper Therapeutics’ Clinical Advances and Market PotentialAugust 14, 2024 | markets.businessinsider.comOptimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial OutcomesAugust 13, 2024 | markets.businessinsider.comMeteorology Monday (8/12/24): Updated 2024 Hurricane Season OutlookAugust 12, 2024 | msn.comOutlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 12, 2024 | globenewswire.comWhy Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?August 9, 2024 | msn.comOutlook Therapeutics (OTLK) Scheduled to Post Earnings on WednesdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Wednesday, August 14, Zacks reports.August 8, 2024 | marketbeat.comOutlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and WebcastAugust 7, 2024 | globenewswire.comUrban Outlook: The Cove NashvilleAugust 6, 2024 | yahoo.comHowmet Aerospace Receives Two-Notch Rating Upgrade from Moody’s and Outlook Upgrade from FitchAugust 6, 2024 | finance.yahoo.comOTLK Nov 2024 10.000 putAugust 6, 2024 | ca.finance.yahoo.comOTLK Aug 2024 7.500 putAugust 6, 2024 | ca.finance.yahoo.comAmerican International Group Inc. Sells 74,302 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)American International Group Inc. lowered its stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 95.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,873 shares of the company's stock aftAugust 3, 2024 | marketbeat.comOutlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024July 30, 2024 | globenewswire.comBNP Paribas Financial Markets Sells 81,876 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)BNP Paribas Financial Markets decreased its holdings in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 94.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,505 shaJuly 29, 2024 | marketbeat.comESG Outlook: Green Story's Akhil Sivanandan on Helping Brands Unlock Sustainability Data PotentialJuly 26, 2024 | msn.comESG Outlook: Ladianne Henderson of WoolTribe on Why Sustainability is Everyone's ProblemJuly 26, 2024 | msn.com Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future. Take these 4 steps today to protect your retirement NOW OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.520.72▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼104▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Coherus BioSciences News Today Champions Oncology News Today Protara Therapeutics News Today Brainstorm Cell Therapeutics News Today Arcturus Therapeutics News Today SIGA Technologies News Today Mereo BioPharma Group News Today ProKidney News Today Silence Therapeutics News Today Corbus Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredUrgent 2024 Election Summit [link enclosed]With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Outlook Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts